Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's done!
Cytodyn market analyze, share, revenue and pps from 2020-2033
Thank you for your appreciated feedback and suggestions for improvement for database or fine tuning assumptions.
This analyze is only for discussions and should not be considered as an investment decision!
Please do your own Due Diligence before considering an investment!
Greetings from Germany
Sunny
AGC & Samsung Biologics ready to ramp up!
AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab
by Diane Hunt on 4/29/20 3:49 PM
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
http://www.agcbio.com/resource-center/news/agcbiologicsmanufactureskeyingredientincovid-19drugleronlimab
Samsung NR excerpt:
Overall, the company reported stable business performance resulting from further utilization improvement at Plant 1 and Plant 2 due to increased market demands. Samsung Biologics continued its business development, client audit and inspection activities through innovative live virtual tours and due diligence, and as a result, the company signed ten new projects in the quarter with local and global clients.
https://www.biospectrumasia.com/news/51/15855/samsung-biologics-inks-new-projects-with-virtual-support.html
CYDY lets get 1st Compassionate Use in May; 2nd EUA approval June!
Samsung & AGC Biologics delivery by June or July for more than 1,2 vials and PPS will take care of itself.
IMO
Samsung Biologics inks new projects with virtual support
27 April 2020 | News
The company reported stable business performance
South Korea based Samsung Biologics has announced Q1 earnings results. The company posted consolidated sales of 207.2 billion Korean Won, operating profit of 62.6 billion Korean Won, and net income of 39.1 billion Korean Won. The company's operating margin was at 30% of revenue attributable to rising utilization rates and reduced SG&A expense.
Overall, the company reported stable business performance resulting from further utilization improvement at Plant 1 and Plant 2 due to increased market demands.
Samsung Biologics continued its business development, client audit and inspection activities through innovative live virtual tours and due diligence, and as a result, the company signed ten new projects in the quarter with local and global clients.
Samsung Biologics has also been effectively responding to the COVID-19 pandemic by operating under its Business Continuity Plan to ensure a stable supply and operations for sustainable services to clients.
The company's rigorous internal safety measures have also proven successful with zero confirmed employee cases and no impact to production schedules to date.
https://www.biospectrumasia.com/news/51/15855/samsung-biologics-inks-new-projects-with-virtual-support.html
UCLA Prof Dr. Yang webinar is starting at 24:00 min at 32:25 min and 51:20 min (question about Rantes) detailed Leronlimab exposure!
Growing support for Leronlimab (Umang Khetarpal MD Texas):
Coronavirus mutates might no vaccine for foreseeable future:
https://translate.google.de/translate?sl=de&tl=en&u=https%3A%2F%2Fwww.scinexx.de%2Fnews%2Fmedizin%2Fwie-stark-ist-das-coronavirus-mutiert%2F
The Implications of Cytodyn's Basket Trial (Blogspot of Biointelligence) with Cytodyn valuation of $70 bn market cap.
https://biotechintelligence.blogspot.com/2020/05/the-implications-of-cytodyns-basket.html?m=1https://biotechintelligence.blogspot.com/2020/05/the-implications-of-cytodyns-basket.html?m=1
Will see what our experts brings to the table.
Short info:
Today I sent all potential treatment targets (list of ohm20 from IH) for Vyrologix (Leronlimab, Pro140) with an extensive analyze by myself, for each disease indication and a future turnover and pps (table from 2020-2030), with all news information, videos, pre-print manuscript and PR's to a well-known (family friend) investment banker and advisor, for one of the largest investment companies.
I am planning another major investment in Cytodyn.
The investment company's approach is, to enter the data into the system and run through possible sales / pps scenarios (Software used by Blackrock nearly similar as Aladdin).
By Wednesday I have extensive feedback on whether my assumed numbers can be realistic and a Go or NoGo for the further and remaining purchase i might will do, after getting results.
Should the report result be positive, neutral or negative in any case i will give a feedback, even if I should not hear from him anymore!
Wish you a nice weekend - Greetings from Germany
Sunny
Tikotiko thanks for your feedback can't answer though BM, so not sure the where pps will be at market close, but this doesn't bother me at all.
Long and strong go cydy
Harvard, Yale and 11 other Universities or clinics joining Cytodyn
Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) and for Mild to Moderate COVID-19
https://clinicaltrials.gov/ct2/show/NCT04347239?term=Cytodyn&cond=Covid&draw=2&rank=2
https://clinicaltrials.gov/ct2/results?cond=Covid&term=Cytodyn+&cntry=&state=&city=&dist=
That is huge!
CYDY Nasdaq Pre Market Quotes:
Pre-Market Volume 9,115
Pre-Market High $3.01 (08:02:44)
Pre-Market Low $2.85 (08:28:07)
Pre-Market Trades
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
08:49:37 $2.92 2,000
08:28:07 $2.85 300
08:27:03 $2.90 100
08:19:47 $2.95 300
08:11:26 $2.90 1,600
08:10:55 $2.90 100
08:10:52 $2.90 300
08:10:45 $2.95 140
08:10:45 $2.95 25
08:10:35 $2.95 160
08:10:35 $2.95 40
08:04:39 $3.00 1,000
08:03:48 $3.00 500
08:03:48 $3.00 1,000
08:02:44 $3.01 550
08:00:48 $3.00 1,000
https://www.nasdaq.com/market-activity/stocks/cydy/pre-market" rel="nofollow" target="_blank" >https://www.nasdaq.com/market-activity/stocks/cydy/pre-market
CYDY Nasdaq Pre Market Quotes:
Pre-Market Volume 9,115
Pre-Market High $3.01 (08:02:44)
Pre-Market Low $2.85 (08:28:07)
Pre-Market Trades
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
08:49:37 $2.92 2,000
08:28:07 $2.85 300
08:27:03 $2.90 100
08:19:47 $2.95 300
08:11:26 $2.90 1,600
08:10:55 $2.90 100
08:10:52 $2.90 300
08:10:45 $2.95 140
08:10:45 $2.95 25
08:10:35 $2.95 160
08:10:35 $2.95 40
08:04:39 $3.00 1,000
08:03:48 $3.00 500
08:03:48 $3.00 1,000
08:02:44 $3.01 550
08:00:48 $3.00 1,000
https://www.nasdaq.com/market-activity/stocks/cydy/pre-market" rel="nofollow" target="_blank" >https://www.nasdaq.com/market-activity/stocks/cydy/pre-market
Inverness Counsel llc/NY bought 15,000 shares of CYDY, as an aperitif!?
https://www.invernesscounsel.com/at-a-glance
Inverness Counsel Portfolio incl. Cytodyn:
https://fintel.io/i/inverness-counsel-llc-ny-
CYDY Insti - Investors:
https://fintel.io/so/us/cydy
2020-05-05 13F Inverness Counsel Llc /ny/ 1.83 15,000 0.00 40 166.67
2020-04-13 13F Livingston Group Asset Management CO (operating as Southport Capital Management) 17,000 45
2020-04-10 13F Diversified Trust Co 1.83 225,500 0.00 601 165.93
2020-04-09 13F Fny Investment Advisers, Llc 1,200 3
2020-02-13 13F InterOcean Capital, LLC 0 -100.00 0 -100.00
2020-02-13 13F L & S Advisors Inc 15,600 16
2020-02-12 13F Glenmede Trust Co Na 100,000 100
Coocooburra can't answer private messages:
I assumed reading this:
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET)
and this:
Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.
After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.
on Nasdaq CYDY page
Nasdaq CYDY Info!
It might be the first sign to be listed anytime soon ?
Nasdaq ready - GO! Is this the first sign to be listed on Nasdaq?
Nasdaq Listing imminent?
CYDY CYDY AFTER HOURS QUOTE
CYDY After-Hours Quotes
Data last updated Invalid date.
This page will resume updating on May 08, 2020 04:00 PM ET.
After-Hours Volume 333,000
After-Hours High $3.09 (16:10:48)
After-Hours Low $3.07 (16:00:01)
After-Hours Trades
After Hours Time (ET) After Hours Price After Hours Share Volume
16:10:48 $3.09 166,000
16:10:47 $3.09 166,000
16:00:01 $3.07 1,000
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment. Investors who anticipate trading during these times are strongly advised to use limit orders.
Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades.
Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.
After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.
Wall broke just in some minutes! Up, up and away we go!
NEWS:
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May
Download as PDF May 04, 2020 6:00am EDT
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the Company is expecting enrollment completion for its 75 patient, Phase 2 double blinded, placebo controlled, randomized study by the end of this month.
CytoDyn has submitted a request to the FDA to grant expanded access, also known as “compassionate use,” to make leronlimab available for patients not eligible for participation in two ongoing clinical trials for coronavirus infections. Many severe and critically-ill patients, who have received off-label immunomodulatory treatments for COVID-19, are excluded from participation in the Company’s Phase 2b/3 clinical trial and could potentially benefit from access to leronlimab under a compassionate use program.
There are 49 COVID-19 patients who have enrolled for treatment with leronlimab through eIND. Four out of 11 critically ill patients with a multitude of pre-existing conditions survived after treatment, and of the next 38 patients, many were extubated, improved, or were discharged.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are very excited about the continuing positive responses from eIND patients following their treatment with leronlimab. We are equally excited about the prospects for patients should the FDA grant access to leronlimab under the compassionate use program. During this past Saturday, we had to overcome many obstacles for two patients who desperately wanted leronlimab. One patient was in the same hospital that enrolled the first 11 patients and the second was a VIP patient in Los Angeles. Under the compassionate use program, we could avoid and quickly overcome this type of stress and turmoil which was very difficult for the patients, their families, the physicians, and CytoDyn. The daughter of a patient who was on a machine used for severe heart and lung failure contacted us directly and expressed her immense gratitude believing leronlimab saved her mother’s life. These are amazing times for us at CytoDyn; with the opportunity to wake up every day with the potential of saving somebody’s life. For sure, I could never have imagined such an incredible honor.”
About Coronavirus Disease 2019
CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. We would like to provide an update that the Biologics License Application (BLA) for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients will be considered completed after the clinical datasets are submitted on May 11, 2020. The clinical datasets are updated to address FDA comments for mock datasets from March 12 and March 20, 2020. After the BLA submission is considered completed, FDA makes a filing decision and sets a PDUFA goal date. CytoDyn has Fast Track designation and a rolling review previously assigned by the FDA and plans to request a priority review for the BLA. A priority review designation means the FDA’s goal is to take action on the marketing application within six months of receipt (compared with 10 months under standard review).
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
Go Leron!Go CYDY! Go Vyrologix! Go Pro140! Go, go, go!!!!
I expect excellent news on Monday!
I am relaxed! I will not go into detail or whisper anything...
Wait and see!
Nader can't sell 4,6 mn of stock as he has not that much Link below:
https://fintel.io/n/pourhassan-nader
Or show me that fact in any Q-Fillings, that he owns 4,6 mn shares!
Nobody can because it is a Fake!
I have never seen SEC-Files with a Zip-Attachment either they are a word or a pdf document!
For me sorry to say it looks like Trojaner, Phishing or Virus contained link!
Targeted Oncology starts spreading the word!
Close to 50 Patients Treated with Leronlimab for COVID-19, Many Recover
Sorry, had to adjust the link!
Targeted Oncology starts spreading the word!
Close to 50 Patients Treated with Leronlimab for COVID-19, Many Recover
Cytodyn will win & will become a worldwide success!
(My personal assessment!)
After all the tireless efforts, for every life that is on the brink this Doctors
- CEO Dr. Nader Pourhassan (Cytodyn)
- Dr. Bruce Patterson, (IncelDx)
- Dr. Jack Lalezari (Crest Clinic SF),
- Dr. Harish Seethamraju (Montefiori Clinic NYC),
- Prof Dr. Yang (UCLA),
- now as well Dr. Jo (youtube) and there are joining more every day to fight for lives.
CEO Dr. Nader Pourhassan made clear with each conference, that they have kept this alive for humanity, for the life of the doomed and for us shareholders of Cytodyn not be diluted for less at it is worth for!!
The postponed publication of the findings on Covid-19 through the use of Vyrologix (Leronlimab) could not have been foreseen, the complexity behind it and the fundamental approach, probably require more time to study and understand the whole content - which has than has to be translated in a laymen word to easily understand what is behind of the "Once in a lifetime drug" that will safe the world for existing and future pandemic outbreaks.
Still, it was important to hold the Wall Street Reporter conference, why?
To commit everyone and future stockholders to it and to inform them about the discoveries and potential behind Cytodyn and Vyrologix.
With every conference there will be more listeners and at some point the time will come where the general public and those responsible, will no longer be able to close their eyes to the truth - because science will convince experts and actual unbelievers and the pressure from the public will be strong so there Vyrologix will be approved by EUA!
Cytodyn is about to show the world what weapon it has against deadly viruses like Covid-19, Mers, Cancer (at least 22 various), HIV, GHvD and many other diseases.
If the United States and those responsible do not wake up soon, other countries (Canada / UK) and companies manager from other BP countries will take partnership with Cytodyn and bring it to success (we all can hope it will not be China or a chinese BP at the end)!
This would allow the United States to take a general-purpose weapon out of its hand - that will not and should not happen! [/ b]
I suspect and hope in less than 10-15 days, Cytodyn will receive funding from organizations and the EUA approval.
The criminal shorters with their lies, false claims have blood on their hands and should be brought to justice - by the US judiciary personally!
They are responsible that it will take longer than expected, as CEO Nader Pourhassan said - if Cytodyn would get to double digits shareprice Cytodyn could raise money without a blink and less dilution to uplist on Nasdaq/NYSE - where the bigger funds and institutions are waiting with open arms to get a piece of this revolutionary drug and Cytodyn as company!
Patience is a virtue and "if USA is what they preach for, than they should take action in all point written above!"
Greetings from Germany and stay healthy!
Realtime German Market links:
Stuttgart
or at ING/DIBA where Dirk Nowitzki the German Wunderkind, Dirkules (from Hercules), Dunking Deutschman or Flying Deutschman does commercials for:
ING-DIBA Stuttgart and Berlin
CEO Dr. Nader Pourhassan said in an interview, Samsung can produce up 3mn vials per month if required (180,000 liter per run). AGM is also able to add significant amount to this vial production.
Why shouldn't Cytodyn be able to uplist in some time, i think all ducks are lined up.
Let's see what the Dr's hav to say at the CC tomorrow!
What if physician decide to use it as extended application for severly ill!
This is not out of the world and it will spread all over if it gives results!
I have patience to get Cytodyn's potential developed either take the world by a breeze or by storm!
Wait and see!
Thanks, lets spread and help the young Family
Link: Please get Leronlimab for Sarah to UK
Support&Follow SaveSarahGray on Facebook!
SaveSarahGray
From the debate of C-45 and C-46
Black Market valued at $77,83 billion - this is much more than ever thought it could be!
May 31: Parliament of Canada
Marco Mendicino Parliamentary Secretary to the Minister of Justice and Attorney General of Canada
"In 2013, Criminal Intelligence Service Canada stated that there were 672 criminal organizations reported in Canada, most of which were located in metropolitan areas, especially in cities where there are ports or a larger economy. CISC also reported that the majority of organized crime groups in Canada are involved in drug trafficking due to the high revenue of Canada's import and export drug market. In this regard, I would just take a moment to note that our government's approach in Bill C-45 aims to deprive criminal organizations and gangs of the very source of revenue they use to continue to profit from the trafficking of illegal drugs.
"Canada's black market is currently valued at approximately $77.83 billion, with drug trafficking accounting for approximately 57%, or $44.5 billion…
"Historically, organized crime consisted of complex and cohesive groups, such as outlaw biker gangs and the mafia, and each group tended to be involved in specific criminal activities for long periods of time….
"Today, organized crime is more fluid; gangs come together for different purposes and work together to achieve their goals, relying on particular skills to carry out a specific criminal act….
"One effective way of combatting organized crime is to prevent these groups from profiting through the black market. In that respect, our government's introduction of Bill C-45, concerning the legalization and strict regulation of cannabis, will have a positive impact on reducing the role of organized crime in the sale of cannabis and will take the illicit profits out of their hands…"
Read more at http://www.stockhouse.com/companies/bullboard?symbol=aphqf&postid=26314968#pqqBhBOGvVc0S0pZ.99
The Makings of a Cannabis Titan
Best read and best team in the cannabis space!
The Makings of a Cannabis Titan
Best read and best team in the cannabis space!